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EgyptAbstract Background and aim: Hepatocellular carcinoma (HCC) has an increasing incidence
worldwide. In this study we aimed to assess the prevalence of HCC among HCV patients in our
center in Mid Delta, Egypt.
Patients and methods: During the period between April 2013 and January 2015, we screened
sequentially chronic HCV patients attending inpatient wards or outpatient Clinic of Tropical Med-
icine Department in Tanta University Hospital for HCC. Individuals with focal lesion in Ultra-
sound (US) and/or serum a-fetoprotein (AFP) level >200 ng/ml were examined by triphasic
computed tomography scanning (CT), and/or magnetic resonance imaging (MRI).
Results: Among 514 HCV patients interviewed and accepted sharing in this study, 90 (17.5%), 144
(28%), and 280 (54.5%) were Child A, B, and C, respectively. We found that 108/514 patients
(21%) had focal lesion detected by US. Also, 89/514 (17.3%) had elevated AFP >200, 13 of them
(14.6%) had no focal lesion on US, but further work up showed HCC in 2 of them. Overall HCC
diagnosis was conﬁrmed in 103 cases, 94 of them (91.3%) were Child B or C. Occurrence of HCC
was signiﬁcantly higher in smokers, diabetics, patients with decompensated liver and those with
positive family history of HCC. Only 20/103 (19.4%) were candidates to curative treatments, 8
of them were Child A asymptomatic and discovered accidentally during screening.el.: +20
258 D.H. Ziada et al.Conclusion: The high prevalence of HCC in our HCV patients (22%) was mainly associated with
decompensated cirrhosis. A national surveillance program for the detection of HCC in cirrhotic
HCV Egyptian patients by combining ultrasound examination and AFP is highly recommended.
 2016 National Cancer Institute, Cairo University. Production and hosting by Elsevier B.V. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Hepatocellular carcinoma (HCC) has an increasing incidence
worldwide. It is the second cause of cancer-related death
worldwide [1,2]. Patients with chronic infection with hepatitis
B or C viruses are at higher risk for developing HCC, and
should be enrolled into surveillance programs using ultrasound
and serum a-fetoprotein (AFP) [3].
In Egypt, HCC is the second most common cancer in men
and the 6th most common cancer in women [4]. Hospital-based
studies from Egypt have reported an overall increase in the rel-
ative frequency of all liver-related cancers in Egypt, from
approximately 4% in 1993 to 7.3% in 2003 [5]. Former studies
in Egypt have shown the increasing importance of HCV infec-
tion in the etiology of liver cancer, estimated to account for
40–50% of cases, and the declining inﬂuence of HBV and
HBV/HCV infection (25% and 15%, respectively) [5,6].
Individuals with focal lesions in ultrasound examination
require further examination with triphasic computed tomogra-
phy (CT), magnetic resonance imaging (MRI), and/or liver
biopsy to conﬁrm a diagnosis of HCC [7].
Treatment is effective in the early stages of the disease.
Unfortunately, HCC is diagnosed in most patients at a time
when curative surgical resection or organ transplantation can-
not be performed because of advanced disease or substantial
impairment of liver function [8].
Barcelona Clinic Liver Cancer (BCLC) staging system is a
widely used classiﬁcation method which takes into account
variables related to tumor stage, liver function, physical status
and cancer-related symptoms (with performance status scale
0–4 where 0 equal normal physical performance and 4 is bed
ridden) to generate a treatment algorithm [9]. In brief, at stage
0 patients are optimal candidates for resection. At stage A
patients are candidates for radical therapies (resection, liver
transplantation or percutaneous treatments). At stage B
patients may beneﬁt from chemoembolization. At stage C
patients may receive new agents as part of RCT and lastly at
stage D patients had end-stage disease and can receive only
symptomatic treatment [10]. This classiﬁcation was suggested
to be best suited for treatment guidance, especially for patients
who could beneﬁt from curative therapies [11,12].
Aim of the work
In this study we aim to assess the prevalence of HCC among
chronic HCV patients in our center in Mid Delta, Egypt.
Patients and methods
Study design
This is a cross-sectional study.Study setting
The study was conducted at the Department of Tropical Med-
icine and Infectious Diseases at Tanta University Hospital,
Tanta, Egypt between April 2013 and January 2015.
Participants
All adult patients with chronic HCV were prospectively
recruited from the outpatient clinics and inpatient wards of
Tropical Medicine and Infectious Diseases Department at
Tanta University Hospital, Tanta, Egypt. All cases were
screened for HCC using ultrasonography and AFP. Individu-
als with solid focal lesion in ultrasound examination, and/or
serum AFP level >200 ng/ml were examined by tri-phasic
CT, and/or MRI to conﬁrm or roll out the diagnosis of
HCC. Abdominal ultrasound examination, Complete blood
counts with manual differential count, liver function tests, fast-
ing blood sugar, and AFP levels were performed for all
patients.
Inclusion criteria
Patients with positive anti HCVAb who had clinical and or
laboratory ﬁndings suggestive of chronic liver disease (portal
hypertension, splenomegaly, hyperbilirubinemia, coagulation
defects. . .etc).
Exclusion criteria
Patients with diagnosed HCC, hepatic metastasis, and prior
HCC treated lesions.
Ethical consideration
– The study protocol has been approved by Tanta University
ethics committee.
– All participating patients provided informed consent before
taking part in the study.
Statistical analysis
Data were analyzed using SPSS version 16.0 (IBM Corp,
Armonk, NY, USA). Quantitative values are expressed as
mean ± SD. Qualitative data were expressed as numbers and
percentages, and the Chi-square test and T-test was applied
to compare the relationship between variables. The sensitivity,
speciﬁcity, positive and negative predictive values of AFP were
assessed at different cut off values using 2  2 contingency
tables. AFP levels were correlated to tumor size and multiplic-
Table 1 Demographic and clinical data of all studied patients.
Parameter HCC
(n= 103)
Chronic
HCV
(n= 411)
p
No % No %
Sex
Male 78 75.7 339 82.5 0.154
Female 25 24.3 72 17.5
Residence
Rural 87 84.5 347 84.4 0.887
Urban 16 15.5 64 15.6
Family history of HCC 22 21.4 50 12.2 0.025*
DM 43 41.7 123 29.9 0.030*
Smoking 48 46.6 176 42.8 0.561
Coﬀee (3 cups/day) 11 10.7 64 15.6 0.271
Hematemesis 78 77.6 263 64 0.033*
Hepatic encephalopathy 46 44.7 136 33.1 0.037*
Rt. hypochondrial pain 72 69.9 224 54.5 0.007*
Ascites 80 77.7 274 66.7 0.042*
Jaundice 76 73.8 260 63.3 0.040*
Anti schistosomal antibodies 89 86.4 377 91.7 0.142
HBsAg+ anti HCVAb 12 11.7 19 4.6 0.014*
Child score
A 9 8.8 81 19.7 <0.001*
B 15 14.6 129 31.4
C 79 76.7 201 48.9
AFP
More than 200 78 75.7 11 2.7 <0.001*
More than 100 79 76.7 47 11.4 <0.001*
Age in year
mean ± SD 57.5
± 8.84
55.53
± 9.96
T= 1.778
Range (35–76) (29–78) P= 0.067
* = Signiﬁcant as analyzed with Chi square/T-test.
Table 2a Contingency table of alpha-fetoprotein (AFP) at
100 ngm/ml and diagnosis of HCC.
AFP HCC
Diagnosed HCC No HCC Total
>100 ngm/ml 79 47 126
<100 ngm/ml 24 364 388
Total 103 411 514
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was considered statistically signiﬁcant for all used tests.
Results
Our patients had age range of 29–78 with an average age of
55.13 ± 9.82 years. Among 514 patients shared in this study,
108 patients (21%) had focal lesion detected by ultrasono-
graphic examination, 32 patients of them (29.6%) had AFP
levels <200 ng/ml. Out of those 108 patients, 101 were con-
ﬁrmed to have HCC while the remaining 7 cases were diag-
nosed by either CT or MRI as follow (focal fat spared
nodule in 3 cases, cirrhotic nodule in 4 cases); these 7 cases
were categorized as not having HCC in statistical analysis.
On the other hand, 89/514 (17.3%) had elevated AFP
>200 ng/ml; 13 of them (14.6%) had no focal lesion in ultra-
sound, but further work up showed HCC in 2 of them. Overall,
HCC diagnosis was conﬁrmed in 103 cases, their demographic
and clinical data are compared to HCV patients and revealed
that age, sex and residence were not signiﬁcantly different
between the two groups. HCC was more prevalent in associa-
tion with positive family history of HCC (it was considered
positive if any of ﬁrst or second degree relatives were diag-
nosed as a HCC patient, regardless of their medical manage-
ment or survival). Patients who suffer diabetes comorbidity,
hematemesis, encephalopathy, right hypochondrial pain,
ascites, jaundice, combined positivity of HCV Ab and HBsAg,
higher Child Pugh score, and high serum AFP were signiﬁ-
cantly more associated with occurrence of HCC (Table 1).
The frequency of AFP elevation above 100, 200 ngm/ml
was presented as contingency table (Table 2 a,b). Accordingly,
AFP has sensitivity, speciﬁcity positive predictive value and
negative predictive values of 76.7%, 88.6%, 62.7%, 93.8%
and 75.7%, 97.3%, 87.6%, 94.1% at cut off value 100 and
200 ng/ml, respectively (Table 3).
AFP was positively correlated to ChildPugh score
(r= 0.217, p= 0.014), but not correlated to tumor size
(r= 0.016, p= 0.437) or multiplicity (r= 0.147, p= 0.069).
The tumor was presented as single focus, 2 foci, and multi-
ple foci in 78, 14 and 11 patients, respectively. Twenty-two
patients had bi-lobar affection. Fifty patients had their tumor
diameter >5 cm (Table 4).
Regarding management of the HCC patients, 54/103
(52.4%) had advanced HCC and got just supportive therapy,
49/103 (47.6%) were treated by different modalities according
to BCLC treatment guidance as following: 5/49 (10.2%) Stage
A underwent surgical excision, 15/49 (30.6%) stage B treated
by radiofrequency (RF) ablation, 8/49 (16.3%) underwent
alcoholic injection, and 21/49 (42.8%) underwent trans-
arterial chemoembolization (TACE).
Discussion
HCC diagnosis was conﬁrmed in 103/514 (20.03%) of our
patients. Similar results were obtained by Atti et al. [14] who
reported that prevalence of HCC among CLD Egyptian
patients was 21%. Egypt and particularly Nile delta has the
highest prevalence of HCV worldwide rendering more patients
prone to post hepatitis C cirrhosis and HCC [11]. Moreover,
many non-viral environmental factors as aﬂatoxin and pesti-
cides are common in this region and can participate in thepathogenesis of HCC through mutations and serious damage
in DNA which can act as cofactors for chronic viral hepatitis
to cause cancer [13,15]. These factors besides the early detec-
tion of some asymptomatic cases can all collaborate to give
this annoying high ﬁgure reported in our patients.
In HCC, male predominance is more obvious in population
at high risk with male to female ratio 3.7:1 [16]. This observa-
tion was conﬁrmed by our results. The M/F ratios were 4/1
and 3/1 in HCC and HCV patients, respectively. Besides the
higher ratio of males in HCV infection, the male predominance
in HCC may be explained by greater exposure of males to
other environmental carcinogens [17], a role for sex hormones,
and higher DNA synthetic activities in male cirrhotic patients
compared to females [17].
Table 4 Tumor criteria in HCC patients (n= 103).
Tumor character No %
Number of tumor foci
 Single 78 75.7
 2 14 13.6
 More than 2 11 10.7
Size of the largest focus
 <3 26 25.3
 3–5 27 26.3
 >5 50 48.5
One lobe aﬀection 81 78.6
Bi-lobar aﬀection 22 21.4
Table 2b Contingency table of of alpha-fetoprotein (AFP) at
200 ngm/ml and diagnosis of HCC.
AFP HCC
Diagnosed HCC No HCC Total
>200 ngm/ml 78 11 89
<200 ngm/ml 25 400 425
Total 103 411 514
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results were reported by Mohamed et al. [16] and Tangkij-
vanich et al. [17] who reported a mean age of 56, and
52.6 years, respectively. As in areas with high risk for HCC,
the mean age for HCC is usually younger [16]; it was not sur-
prising to ﬁnd no signiﬁcant difference in age between HCV
and HCC patients.
In this study, more than 84% of our patients were from
rural areas. These results are explained as most of Mid Delta
are rural areas. Also, El-Zayadi et al. [5] stated that 75.2%
of his HCC population resided in rural areas. This higher
prevalence may be explained by the nature of rural area resi-
dences where the population is more exposed to environmental
pollutants as pesticides and herbicides.
Diabetes is associated with a 2–3-fold increase in the risk of
HCC; regardless of the presence of other major HCC risk fac-
tors [18]. This was in accordance with the signiﬁcant higher fre-
quency of DM in our HCC patients.
Smoking increases the risk of HCC in patients with viral
hepatitis. Cigarettes are a major source of 4-aminobiphenyl;
a hepatic carcinogen which has been implicated as a causal risk
factor for HCC. Tobacco smoking is associated with reduction
of tumor suppressor gene p53 and accumulation of excess iron
in hepatocytes in heavy smokers, which induces ﬁbrosis and
favors development of HCC [19,20]. In our study, there was
no signiﬁcant difference between percent of smokers in both
groups. This was in agreement with Mori et al. [21] who ﬁnd
the increased risk of HCC in smokers to be non-signiﬁcant
after adjusting for age and gender, and Franceschi et al. [22]
who concluded that tobacco smoking was unrelated to overall
HCC risk.
Coffee consumption of more than 3 cups per day may be
associated with reduced risk to HCC [23]. In our study, this
degree of coffee consumption was less frequent in HCC
patients. Yet the difference was not statistically signiﬁcant.
Co-infection with HBV was signiﬁcantly higher in HCC
compared to HCV groups (11.7% versus 4.6%). These results
were in agreement with Zampino et al. [24] who stated that
HBV and HCV co-infection is associated with more rapid pro-
gression to HCC.
The frequency of Rt. hypochondrial pain, Jaundice,
Ascites, Hepatic encephalopathy, and hematemesis was signif-
icantly higher in HCC patients compared to chronic HCVTable 3 Diagnostic value of alpha-fetoprotein (AFP) in detection o
AFP ngm/ml Sensitivity Speciﬁcity
>100 76.7% (79/103) 88.6% (364/411)
>200 75.7% (78/103) 97.3% (400/411)patients. This explained that HCC development is a leading
cause for deterioration of CLD patients [25].
Abdominal ultrasound is the most common imaging
modality used in the surveillance of HCC [26]. However, the
accuracy of ultrasound is dependent on the operators and their
ability to differentiate HCC from non-neoplastic lesions such
as regenerative nodules [27]. In our work, ultrasound was able
to detect focal lesion in most cases of HCC which conﬁrms its
leading screening role. Adding AFP examination augments the
screening role of ultrasound. However, the rise in the serum
AFP level did not correlate with the tumor size or number.
The lack of correlation could be explained by the fact that
tumor differentiation and its ability to secrete AFP are more
important than the tumor size in determining the level of
AFP produced by HCC [28]. Sawabu et al. [29] declared that
small tumors tend to express lower levels of AFP, although
there is no clear direct relation between the tumor size and
AFP levels, because individual tumors have different capacities
for AFP synthesis, also it is difﬁcult to measure viable tumor
cell mass accurately and thereby to investigate the true corre-
lation between viable tumor mass and AFP.
In the current study, there was a signiﬁcant positive corre-
lation between AFP and the Child Pugh score in HCC group.
This may be attributed to the presence of underlying chronic
liver disease with subsequent cirrhosis and the progressive
deterioration of the liver condition. Elevated AFP in these
patients is not indicative but may be only suggestive of HCC
and needs further work-up to exclude HCC [26]. At cut off
value 200 ng/ml, we found AFP to be 75.7% sensitive and
97.3% speciﬁc in diagnosis of HCC, which may encourage
using it in screening being a cheap and easy test. When we test
a cut off value of 100 ng/ml, AFP was 76.7% sensitive, but
speciﬁcity dropped to 88.6%. Cost effective studies are needed
before adopting 100 ng/ml as a cut off value for HCC in cir-
rhotic patients.
In spite of the obvious advantages of early intervention in
HCC and the very limited treatment options for patients in
advanced stages, surveillance measures are not routinely
implemented [30]. A recent Canadian study found that mostf HCC in cirrhotic patients.
Positive predictive value Negative predictive value
62.7% (79/126) 93.8% (364/388)
87.6% (78/89) 94.1% (400/425)
Hepatocellular carcinoma in chronic hepatitis C patients 261patients with HCC referred to a tertiary liver treatment center
were in palliative stages [31]. Regarding the treatment options
for our 103 HCC patients, 54/103 (52.4%) had advanced HCC
(stage C or D) and just received supportive therapy, while,
49/103 (47.9%) were treated with different modalities as fol-
lows: 5/49 (10.2%) surgical excision, 15/49 (30.7%) radiofre-
quency (RF) ablation, 8/49 (16.3%) alcoholic injection, and
21/49 (42.8%) trans arterial chemo embolization (TACE).
So, only 20/103 (19.4%) were diagnosed in stages allowing
for curative treatment. These ﬁndings stress on the importance
of strict implementation of routine screening and surveillance
for patients with HCV and cirrhosis to detect liver cancer in
early stages where there is a chance for curative therapy.
Conclusion
The prevalence of HCC in our patients was 22%. HCC was
more prevalent in HCV patients with positive family history
of HCC, DM, HBV comorbidity, right hypochondrial pain,
hematemesis, encephalopathy, ascites, jaundice, and higher
Child Pugh score indicating higher prevalence in decompen-
sated cirrhosis.
Only 19.4% of HCC patients were diagnosed in the early
stage rendering them candidate for curative treatment. A
national surveillance program for HCC in cirrhotic HCV
Egyptian patients by combining ultrasound examination and
AFP is highly recommended.
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